Skip to main content

Table 5 Incidence rates per 100,000 person-years of malaria cases

From: Baseline incidence of meningitis, malaria, mortality and other health outcomes in infants and young sub-Saharan African children prior to the introduction of the RTS,S/AS01E malaria vaccine

 

Kombewa, Kenya

Kintampo, Ghana

Navrongo, Ghana

Overall

N = 1743

N = 3488

N = 1143

N = 6374

n

PY

Value (95% CI)

n

PY

Value (95% CI)

n

PY

Value (95% CI)

n

PY

Value (95% CI)

Malaria

 Any

381

810

47,048 (42,442, 52,018)

1010

1714

58,928 (55,350, 62,678)

79

550

14,364 (11,372, 17,902)

1470

3074

47,824 (45,411, 50,333)

 Uncomplicated

364

810

44,949 (40,449, 49,812)

972

1714

56,711 (53,202, 60,392)

75

550

13,637 (10,726, 17,094)

1411

3074

45,905 (43,541, 48,364)

 Severe malaria

17

810

2099 (1223, 3361)

38

1714

2217 (1569, 3043)

4

550

727 (198, 1862)

59

3074

1919 (1461, 2476)

 Cerebral malaria

0

810

0 (0, 456)

1

1714

58 (1, 325)

0

550

0 (0, 671)

1

3074

33 (1, 181)

P. falciparum

 Uncomplicated

277

810

34,205 (30,296, 38,480)

813

1714

47,434 (44,229, 50,810)

74

550

13,455 (10,565, 16,891)

1164

3074

37,869 (35,725, 40,109)

 Severe

15

810

1852 (1037, 3055)

38

1714

2217 (1569, 3043)

4

550

727 (198, 1862)

57

3074

1854 (1405, 2403)

  1. According-to-protocol cohort, 5 to 17 months age-group N, Number of study participants at risk during a follow-up period of approximately 6 months after the 3rd virtual vaccine dose; n, number of cases reported during that follow-up period; PY: person-years; CI: confidence intervals
  2. Malaria cases were confirmed by rapid diagnostic test and/or microscopy